| http://www.w3.org/ns/prov#value | - ed underwritten initial public offering of 600,000 shares of common stock, bringing expected total gross proceeds from the offering to $6,900,000, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.
|
